A dietary intervention for chronic diabetic neuropathy pain: A randomized controlled pilot study

Nutrition and Diabetes

Volumn 5, Issue 5, 2015, Pages

  Bunner, A E ^a   Wells, C L ^a   Gonzales, J ^a   Agarwal, U ^b   Bayat, E ^c   Barnard, N D ^a,d  

^a PHYSICIANS COMMITTEE FOR RESPONSIBLE MEDICINE   (United States)

^b CALIFORNIA STATE UNIVERSITY   (United States)

^c George Washington Medical Faculty Associates   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; CHOLESTEROL; CYANOCOBALAMIN; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREGABALIN;

ADULT; AGED; ANALOG WORST PAIN SCALE; ANIMAL PRODUCT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIASTOLIC BLOOD PRESSURE; DIET; DIETARY COMPLIANCE; DRUG WITHDRAWAL; ELECTROCHEMISTRY; FEMALE; HUMAN; HYPOGLYCEMIA; LOW FAT DIET; MALE; MCGILL PAIN QUESTIONNAIRE; MICHIGAN NEUROPATHY SCREENING INSTRUMENT; NEUROLOGIC DISEASE ASSESSMENT; NEUROPATHIC PAIN; NEUROPATHY TOTAL SYMPTOM SCORE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORFOLK QUALITY OF LIFE QUESTIONNAIRE; PAIN ASSESSMENT; PILOT STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SKIN CONDUCTANCE; SYSTOLIC BLOOD PRESSURE; VISUAL ANALOG SCALE; VITAMIN SUPPLEMENTATION; WEIGHT CHANGE;

EID: 84987803020     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2015.8     Document Type: Article

References (32)

1. Kles KA, Vinik AI. Pathophysiology and treatment of diabetic peripheral neuropathy: the case for diabetic neurovascular function as an essential component. Curr Diabetes Rev 2006; 2: 131-145.
2. Wu SC, Wrobel JS, Armstrong DG. Assessing the impact of pharmacologic intervention on the quality of life in diabetic peripheral neuropathic pain and fibromyalgia. Pain Med 2007; 8: S33-S42.
3. Dobretsov M, Romanovsky D, Stimers JR. Early diabetic neuropathy: triggers and mechanisms. World J Gastroenterol 2007; 13: 175-191.
4. Calcutt NA, Backonja MM. Pathogenesis of pain in peripheral diabetic neuropathy. Curr Diab Rep 2007; 7: 429-434.
5. Barnard ND, Cohen J, Jenkins DJ, Turner-McGrievy G, Gloede L, Jaster B et al. A low-fat vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes. Diabetes Care 2006; 29: 1777-1783.
6. Yokoyama Y, Barnard ND, Levin SM, Watanabe M. Vegetarian diets and glycemic control in diabetes: a systematic review and meta-Analysis. Cardiovasc Diagn Ther 2014; 4: 373-382.
7. Ferdowsian HR, Barnard ND, Hoover VJ, Katcher HI, Levin SM, Green AA et al. A multicomponent intervention reduces body weight and cardiovascular risk at a GEICO corporate site. Am J Health Promot 2010; 24: 384-387.
8. Yokoyama Y, Nishimura K, Barnard ND, Takegami M, Watanabe M, Sekikawa A et al. Vegetarian diets and blood pressure: a meta-Analysis. JAMA Intern Med 2014; 174: 577-587.
9. Barnard ND, Scialli AR, Turner-McGrievy G, Lanou AJ. Acceptability of a low-fat vegan diet compares favorably to a step II diet in a randomized, controlled trial. J Cardiopulm Rehabil 2004; 24: 229-235.
10. Smith AG, Russell J, Feldman EL, Goldstein J, Peltier A, Smith S et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care 2006; 29: 1294-1299.
11. Crane MG, Sample C. Regression of diabetic neuropathy with total vegetarian (vegan) diet. J Nutr Med 1994; 4: 431-439.
12. Savage DG, Lindenbaum J, Stabler SP, Allen RH. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med 1994; 96: 239-246.
13. Bastyr EJ 3rd, Price KL, Bril V. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clin Ther 2005; 27: 1278-1294.
14. Bax G, Fagherazzi C, Piarulli F, Nicolucci A, Fedele D. Reproducibility of Michigan Neuropathy Screening Instrument (MNSI). A comparison with tests using the vibratory and thermal perception thresholds. Diabetes Care 1996; 19: 904-905.
15. Bril V. NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. Eur Neurol 1999; 41: 8-13.
16. Sun Y, Lai MS, Lu CJ. Effectiveness of vitamin B12 on diabetic neuropathy: systematic review of clinical controlled trials. Acta Neurol Taiwan 2005; 14: 48-54.
17. Calvet JH, Dupin J, Winiecki H, Schwarz PE. Assessment of small fiber neuropathy through a quick, simple and non invasive method in a German diabetes outpatient clinic. Exp Clin Endocrinol Diabetes 2013; 121: 80-83.
18. Yajnik CS, Kantikar VV, Pande AJ, Deslypere JP. Quick and simple evaluation of sudomotor function for screening of diabetic neuropathy. ISRN Endocrinol 2012; 2012: 103714.
19. Casellini CM, Parson HK, Richardson MS, Nevoret ML, Vinik AI. Sudoscan, a noninvasive tool for detecting diabetic small fiber neuropathy and autonomic dysfunction. Diabetes Technol Ther 2013; 15: 948-953.
20. Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. J Man Manip Ther 2009; 17: 163-170.
21. Graham C, Bond SS, Gerkovich MM, Cook MR. Use of the McGill pain questionnaire in the assessment of cancer pain: replicability and consistency. Pain 1980; 8: 377-387.
22. Kremer E, Atkinson JH Jr. Pain measurement: construct validity of the affective dimension of the McGill Pain Questionnaire with chronic benign pain patients. Pain 1981; 11: 93-100.
23. Vinik EJ, Hayes RP, Oglesby A, Bastyr E, Barlow P, Ford-Molvik SL et al. The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther 2005; 7: 497-508.
24. Vinik EJ, Paulson JF, Ford-Molvik SL, Vinik AI. German-translated Norfolk quality of life (QOL-DN) identifies the same factors as the English version of the tool and discriminates different levels of neuropathy severity. J Diabetes Sci Technol 2008; 2: 1075-1086.
25. Tanenberg RJ, Irving GA, Risser RC, Ahl J, Robinson MJ, Skljarevski V et al. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison. Mayo Clin Proc 2011; 86: 615-626.
26. Beck A, Steer R, Brown G. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation, 1996.
27. Macrodimitris S, Endler N. Coping, control and adjustment in Type II diabetes. Health Psychol 2001; 20: 208-216.
28. Barnard ND, Scialli AR, Turner-McGrievy G, Lanou AJ, Glass J. The effects of a lowfat, plant-based dietary intervention on body weight, metabolism, and insulin sensitivity. Am J Med 2005; 118: 991-997.
29. Berkow SE, Barnard N. Vegetarian diets and weight status. Nutr Rev 2006; 64: 175-188.
30. Barnard N, Akhtar A, Nicholson A. Factors that facilitate dietary change. Arch Fam Med 1995; 4: 153-158.
31. Reinstatler L, Qi YP, Williamson RS, Garn JV, Oakley GP Jr. Association of biochemical B(1)(2) deficiency with metformin therapy and vitamin B(1)(2) supplements: the National Health and Nutrition Examination Survey, 1999-2006. Diabetes Care 2012; 35: 327-333.
32. Kountz D. Special considerations of care and risk management for African American patients with type 2 diabetes mellitus. J Natl Med Assoc 2012; 104: 265-273.